Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
The Methodist Hospital Research Institute
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
Dragonfly Therapeutics
Immunocore Ltd
Seagen Inc.
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Emory University
Institute of Oncology Ljubljana
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
University of Pittsburgh
Highlight Therapeutics
Lytix Biopharma AS
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Incyte Corporation
MacroGenics
Yale University
Sheba Medical Center
Mayo Clinic
Regeneron Pharmaceuticals
Mural Oncology, Inc
Thomas Jefferson University
Seagen Inc.
Syndax Pharmaceuticals
GlaxoSmithKline
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Haukeland University Hospital
Amgen
University of Pennsylvania
Eli Lilly and Company
Vincerx Pharma, Inc.
Abramson Cancer Center at Penn Medicine
University of Pittsburgh
Hoffmann-La Roche
University of Colorado, Denver
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University Medical Center Groningen
Eli Lilly and Company